Streetbeat News

ERNA

Eterna Therapeutics Inc.

https://www.brooklynitx.com

Industry

Biotechnology

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

The article highlights significant intraday movements in health care stocks on Monday. Structure Therapeutics (GPCR) saw a 71% increase, while Concord Medical Services (CCM) rose by 55.96%. On the downside, CNS Pharma (CNSP) and Galera Therapeutics (GRTX) experienced declines of 32.2% and 31.67%, respectively.

Portfolio Pulse from Benzinga Insights

June 03, 2024 | 4:31 pm

Eterna Therapeutics Inc. announced the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity, aimed at improving the treatment of inflammatory diseases. This advancement, presented at the ASGCT Annual Meeting, promises to address batch-to-batch inconsistencies, promote in vivo persistence, and enhance cell effector function.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 12:07 pm

Eterna Therapeutics Inc received a notice from Nasdaq on March 19, indicating non-compliance with Nasdaq Listing Rule 5550(B)(1), according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 8:37 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. Revance Therapeutics, Eterna Therapeutics, Connect Biopharma Hldgs, Celularity, Trxade Health, and Windtree Therapeutics were among the gainers, with increases ranging from 12.19% to 16.5%. On the downside, GRI Bio, Sharps Technology, Biofrontera, Kiora Pharmaceuticals, Cadrenal Therapeutics, and Corbus Pharmaceuticals experienced declines between 9.04% and 31.8%.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 1:06 pm

In Thursday's pre-market session, several healthcare stocks showed significant movement. Kiora Pharmaceuticals, Salarius Pharmaceuticals, HOOKIPA Pharma, Eterna Therapeutics, Akso Health Group, and OpGen experienced notable gains, with increases ranging from 18.03% to 48.3%. Conversely, Revelation Biosciences, OneMedNet, Bullfrog AI Holdings, Jin Medical International, Trinity Biotech, and 180 Life Sciences saw declines, with decreases ranging from 12.15% to 59.7%. These movements reflect the volatile nature of healthcare stocks in the market.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 1:06 pm

In Thursday's pre-market session, several healthcare stocks experienced significant movements. Aclarion (ACON) saw a 70% increase, while TRACON Pharma (TCON) rose by 47.92%. Eterna Therapeutics (ERNA) and Passage Bio (PASG) also gained, with increases of 22.8% and 21.23%, respectively. Conversely, bluebird bio (BLUE) dropped by 51.9%, and other companies like Jin Medical International (ZJYL), argenx (ARGX), and Xilio Therapeutics (XLO) saw declines ranging from 17.89% to 30.63%.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 1:07 pm

Eterna Therapeutics has announced the appointment of Sanjeev Luther as President and CEO, effective January 1, 2024. He will succeed Matt Angel in these roles.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 9:17 pm

IAF, LLC has filed a 13G with the SEC, disclosing a 9.99% passive stake in Eterna Therapeutics as of December 14. This information is based on the latest SEC filing.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 8:28 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant movements. Aclarion (ACON) saw a 75.8% increase, while Longeveron (LGVN) rose by 43.07%. Passage Bio (PASG), Dare Bioscience (DARE), Eterna Therapeutics (ERNA), and Kintara Therapeutics (KTRA) also saw upward movements. Conversely, bluebird bio (BLUE), Jin Medical International (ZJYL), argenx (ARGX), Xilio Therapeutics (XLO), Ontrak (OTRK), and Panbela Therapeutics (PBLA) experienced declines, with bluebird bio dropping 45.3%.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 1:07 pm

Eterna Therapeutics Inc. has entered into a securities purchase agreement with accredited investors to sell around $9.2 million in senior convertible promissory notes and warrants. These warrants allow for the purchase of approximately 9.58 million shares of common stock. The private placement transaction was priced at-the-market under Nasdaq rules. The company anticipates an initial closing with proceeds of about $7.8 million on December 15, 2023, and the remaining funds by January 15, 2023.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 7:00 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.